Human Vitreous Concentration of Brimonidine after Instillation of Aibeta Combination Ophthalmic Solutio
- Conditions
- Idiopathic epiretinal membrane, macular hole
- Registration Number
- JPRN-jRCTs051200008
- Lead Sponsor
- Inatani Masaru
- Brief Summary
The brimonidine concentration in the vitreous following topical application of Aibeta was above the effective concentration of neuroprotection in humans. Aibeta achieved brimonidine and timolol distribution in the aqueous humor that were comparable to those for the single-drug formulations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 9
1)Patients with written informed consent obtained after adequate explanation on participating the study
2)Male or female, 20 years of age or older
3)Patients who undergo vitrectomy for idiopathic epiretinal membrane or macular hole
1)Patients with ocular inflammation
2)Patients with vitreous hemorrhage
3)Patients with proliferative diabetic retinopathy
4)Patients with severe corneal epithelium disorder
5)Patients with contraindications or patients in whom precautions are required for the use of
Brimonidine/Timolol fixed combination.
6)Patients with a history of serious side effects against alpha 2-adrenergic receptor agonist or
beta-adrenergic receptor inhibitor
7)Patients who have been considered inappropriate as study subjects by doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method